Last reviewed · How we verify

Systemic Therapy/Standard of Care

Memorial Sloan Kettering Cancer Center · Phase 3 active Small molecule

Systemic Therapy/Standard of Care is a PD-1 inhibitor Small molecule drug developed by Memorial Sloan Kettering Cancer Center. It is currently in Phase 3 development for Metastatic non-small cell lung cancer, PD-L1 positive, Metastatic melanoma, Head and neck squamous cell carcinoma.

This drug targets the PD-1 receptor to inhibit cancer cell growth.

This drug targets the PD-1 receptor to inhibit cancer cell growth. Used for Metastatic non-small cell lung cancer, PD-L1 positive, Metastatic melanoma, Head and neck squamous cell carcinoma.

At a glance

Generic nameSystemic Therapy/Standard of Care
SponsorMemorial Sloan Kettering Cancer Center
Drug classPD-1 inhibitor
TargetPD-1
ModalitySmall molecule
Therapeutic areaOncology
PhasePhase 3

Mechanism of action

By binding to PD-1, the drug prevents cancer cells from evading the immune system, allowing the body's immune cells to attack and destroy the cancer cells. This leads to an anti-tumor response and potentially prolonged survival in patients with certain types of cancer.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Systemic Therapy/Standard of Care

What is Systemic Therapy/Standard of Care?

Systemic Therapy/Standard of Care is a PD-1 inhibitor drug developed by Memorial Sloan Kettering Cancer Center, indicated for Metastatic non-small cell lung cancer, PD-L1 positive, Metastatic melanoma, Head and neck squamous cell carcinoma.

How does Systemic Therapy/Standard of Care work?

This drug targets the PD-1 receptor to inhibit cancer cell growth.

What is Systemic Therapy/Standard of Care used for?

Systemic Therapy/Standard of Care is indicated for Metastatic non-small cell lung cancer, PD-L1 positive, Metastatic melanoma, Head and neck squamous cell carcinoma.

Who makes Systemic Therapy/Standard of Care?

Systemic Therapy/Standard of Care is developed by Memorial Sloan Kettering Cancer Center (see full Memorial Sloan Kettering Cancer Center pipeline at /company/memorial-sloan-kettering-cancer-center).

What drug class is Systemic Therapy/Standard of Care in?

Systemic Therapy/Standard of Care belongs to the PD-1 inhibitor class. See all PD-1 inhibitor drugs at /class/pd-1-inhibitor.

What development phase is Systemic Therapy/Standard of Care in?

Systemic Therapy/Standard of Care is in Phase 3.

What are the side effects of Systemic Therapy/Standard of Care?

Common side effects of Systemic Therapy/Standard of Care include Pneumonitis, Hypothyroidism, Diarrhea.

What does Systemic Therapy/Standard of Care target?

Systemic Therapy/Standard of Care targets PD-1 and is a PD-1 inhibitor.

Related